RxDoctor Payments Data

Earl John Soileau, MD

Family Medicine · Lake Charles, LANPI 1912999707

Payments from drug & device makers

$5,625in general payments, 2019–2025

Across 39 payments — averaging $144.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corium, LLC$5K
  • Alkermes, Inc.$141
  • Astellas Pharma US Inc$64
  • Novo Nordisk$55
  • Daiichi Sankyo Inc.$46
  • Supernus Pharmaceuticals, Inc.$37
  • plus $82 from 4 others

What the payments were for

  • Consulting fees$3,38060%
  • Speaking & faculty fees$1,40025%
  • Travel & lodging$942%
  • Food & beverage$75113%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,625 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$35,333
Medicare patients
193
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$43,142
JanuviaSitagliptin Phosphate39$34,240
OzempicSemaglutide17$32,921
MounjaroTirzepatide18$19,682
VraylarCariprazine Hcl11$15,655
RybelsusSemaglutide11$10,345
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$3,887
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine81$3,121
Naproxen13$1,959
Acarbose50$1,850
Divalproex Sodium32$1,632
Levothyroxine Sodium201$1,454
Metformin Hcl ErMetformin Hcl116$1,358
Bupropion Hcl SrBupropion Hcl51$1,193
Trazodone Hcl91$1,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$55$43,26628 claims
Johnson & JohnsonInvega Sustenna$26$43,14213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →